相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
Mark J. Alberts et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2022)
Obesity and atrial fibrillation: making inroads through fat
Saad Javed et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation
Alexandros Briasoulis et al.
CARDIOVASCULAR DRUGS AND THERAPY (2021)
Safety and Efficacy of Rivaroxaban and Apixaban in Patients with Increased Body Mass: a Systematic Review
Margaret M. Buck et al.
CLINICAL DRUG INVESTIGATION (2021)
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
Jeffrey S. Berger et al.
CURRENT MEDICAL RESEARCH AND OPINION (2021)
Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study
Xiaoye Li et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-analysis
Mohammed Mhanna et al.
AMERICAN JOURNAL OF THERAPEUTICS (2021)
Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes
Matthew R. Weir et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2021)
Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight
Isaac J. Perales et al.
ANNALS OF PHARMACOTHERAPY (2020)
Patients with higher body mass index treated with direct/novel oral anticoagulants (DOAC/NOAC) for atrial fibrillation experience worse clinical outcomes
Marko Lucijanic et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2020)
Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study
Steve Deitelzweig et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Characteristics and anticoagulant treatment status of elderly non-valvular atrial fibrillation patients with a history of catheter ablation in Japan: Subanalysis of the ANAFIE registry
Ken Okumura et al.
JOURNAL OF CARDIOLOGY (2020)
Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis
Olivia S. Costa et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2020)
Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation
Kazuhiko Kido et al.
ANNALS OF PHARMACOTHERAPY (2019)
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
Margarita Kushnir et al.
LANCET HAEMATOLOGY (2019)
Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs
Alex C. Spyropoulos et al.
THROMBOSIS RESEARCH (2019)
Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function
Jonathan Salcedo et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2019)
Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
Eric D. Peterson et al.
AMERICAN HEART JOURNAL (2019)
Economic burden of thromboembolic and hemorrhagic complications in non-valvular atrial fibrillation in Algeria (the ELRAGFA study)
Mounir Bouame et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Body mass index and the risk of new-onset atrial fibrillation in middle-aged adults
Anat Berkovitch et al.
AMERICAN HEART JOURNAL (2016)
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
K. Martin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Rivaroxaban in atrial fibrillation
Mariano A. Giorgi et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2012)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Obesity and the risk of new-onset atrial fibrillation
TJ Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation
AH Abdelhafiz
CLINICAL THERAPEUTICS (2001)
分享论文
